MarketPulse

immunology drugs

2 articles
The Motley FoolThe Motley Fool··David Jagielski, Cpa

AbbVie Stock Trades at Bargain Valuation as New Drugs Offset Humira Decline

AbbVie stock down 11% YTD but trades at 14x forward P/E with 0.49 PEG, suggesting undervaluation amid strong new drug momentum and 3.4% dividend yield.
ABBVXLVdividend yieldhealthcare stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

CVS and AbbVie Emerge as Healthcare Recovery Plays Amid Market Downturn

CVS and AbbVie emerge as recovery opportunities post-market pullback, leveraging diversified operations and immunology momentum respectively, with strong dividend backing investor confidence.
ABBVCVSdividend stockshealthcare stocks